2American Thoracic Society; Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia [ J ]. Am J Respir Crit Care Med, 2005, 171 (4) : 388-416.
3Freire AT, Melnyk V, Kim MJ, et al. Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia [ J]. Diagn Mierobiol Infect Dis, 2010, 68 (2): 140-151.
4Barbour A, Schmidt S, Ma B, et al. Clinical pharmacokinetics and pharmacodynamies of tigeeycline [ J ]. Clin Pharmacokinet, 2009, 48 (9): 575-584.
6Ramirez J, Dartois N, Gandjini H, et al. Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital- acquired pneumonia [ J ]. Antimicrob Agents Chemother, 2013, 57 (4): 1756-1762.
7File TM Jr. Recommendations for treatment of hospital-acquired and ventilator-associated pneumonia: review of recent international guidelines [ J]. Clin Infect Dis, 2010, 51 Suppl 1:S42-47.
8Sader HS, Farrell D J, Jones RN. Tigecycline activity tested against muhidrug-resistant Enterobacteriaceae and Acinetobacter spp [ J]. Diagn Microbiol Infect Dis, 2011, 69 (2) : 223-227.
9Department of Health and Human Services. Cancer therapy evaluation program, common terminology criteria for adverse events, v. 3.0. [M]. 2006.
10Safdar N, Dezfulian C, Collard HR, et al. Clinical and economic consequences of ventilator-associated pneumonia: a systematic review [J]. Crit Care Med, 2005, 33 (10) : 2184-2193.
